A company that patented a process for using placental tissue as bioimplants has mostly passed Section 101′s natural-phenomenon test.
U.S. District Judge Virginia Emerson Hopkins of the Northern District of Alabama ruled Tuesday that there was sufficient inventive concept in MiMedx Group Inc.’s methods of separating, labeling and reconstituting layers of tissues to render 14 of 17 claims patent eligible.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
